This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
intensive care | 2107 |
stem cell | 1964 |
mg kg | 1588 |
cell transplantation | 1364 |
care unit | 1274 |
mechanical ventilation | 1126 |
critically ill | 1072 |
septic shock | 984 |
median age | 885 |
bone marrow | 880 |
patients received | 856 |
risk factors | 822 |
ill patients | 821 |
peripheral blood | 798 |
patients admitted | 780 |
mean age | 776 |
two groups | 746 |
one patient | 726 |
hematopoietic stem | 689 |
significantly higher | 660 |
control group | 653 |
critical care | 642 |
overall survival | 636 |
clinical signs | 623 |
cardiac arrest | 608 |
statistically significant | 607 |
brain injury | 602 |
significant difference | 590 |
study design | 569 |
conditioning regimen | 559 |
cd cells | 542 |
ng ml | 539 |
stem cells | 528 |
respiratory failure | 521 |
acute gvhd | 521 |
mortality rate | 518 |
two patients | 510 |
chronic gvhd | 508 |
median time | 508 |
blood pressure | 505 |
hospital mortality | 492 |
case studies | 489 |
high risk | 487 |
significant differences | 485 |
patients undergoing | 482 |
background case | 481 |
icu admission | 479 |
host disease | 476 |
median follow | 472 |
acute respiratory | 467 |
mg dl | 466 |
organ failure | 455 |
icu patients | 447 |
retrospective study | 445 |
pg ml | 444 |
adverse events | 438 |
university hospital | 436 |
years old | 424 |
multivariate analysis | 423 |
apache ii | 421 |
patients receiving | 407 |
adult patients | 398 |
logistic regression | 396 |
icu stay | 394 |
design method | 388 |
patients treated | 384 |
hospital stay | 383 |
free survival | 378 |
blood flow | 378 |
ml kg | 375 |
results finding | 375 |
body weight | 360 |
study period | 351 |
traumatic brain | 350 |
allogeneic hematopoietic | 348 |
consecutive patients | 342 |
significantly lower | 340 |
within hours | 337 |
gvhd prophylaxis | 336 |
blood samples | 333 |
present study | 330 |
performed using | 323 |
patients without | 321 |
cd cd | 320 |
respiratory distress | 317 |
side effects | 316 |
renal failure | 316 |
red blood | 315 |
neurocritical care | 315 |
whole blood | 311 |
prospective study | 310 |
emergency department | 308 |
mechanically ventilated | 306 |
observational study | 302 |
three patients | 301 |
subarachnoid hemorrhage | 300 |
risk factor | 300 |
days post | 296 |
statistical analysis | 295 |
lung injury | 294 |
septic patients | 294 |
complete remission | 290 |
flow cytometry | 288 |
clinical trial | 288 |
within days | 287 |
patients died | 286 |
patients underwent | 286 |
heart rate | 286 |
four patients | 286 |
care units | 285 |
poor outcome | 285 |
ischemic stroke | 284 |
cardiac surgery | 280 |
th day | 280 |
allogeneic stem | 278 |
severe sepsis | 276 |
cord blood | 272 |
kg day | 272 |
cohort study | 271 |
long term | 271 |
clinical trials | 267 |
year old | 263 |
minimally invasive | 260 |
sofa score | 260 |
five patients | 259 |
cumulative incidence | 257 |
lymph nodes | 257 |
retrospective analysis | 256 |
ct scan | 256 |
united states | 256 |
blood stem | 256 |
cardiac output | 254 |
blood cell | 254 |
among patients | 251 |
medical center | 251 |
ii score | 249 |
blood loss | 249 |
unrelated donor | 249 |
regression analysis | 247 |
least one | 244 |
weight loss | 243 |
nk cells | 241 |
central venous | 241 |
high dose | 240 |
increased risk | 240 |
arterial pressure | 240 |
ethics regulations | 238 |
immune response | 238 |
arterial blood | 234 |
allogeneic hsct | 233 |
multiple myeloma | 232 |
first days | 231 |
inflammatory response | 231 |
graft failure | 230 |
significantly different | 229 |
significantly associated | 227 |
platelet count | 227 |
respiratory tract | 225 |
blood cells | 225 |
included patients | 225 |
univariate analysis | 225 |
graft versus | 224 |
distress syndrome | 223 |
day mortality | 223 |
abdominal pain | 223 |
cmv reactivation | 221 |
pao fio | 220 |
status epilepticus | 219 |
inclusion criteria | 218 |
factors associated | 218 |
first day | 218 |
significant increase | 216 |
patients developed | 213 |
results suggest | 213 |
case report | 213 |
primary outcome | 213 |
multiple organ | 213 |
significantly increased | 212 |
may also | 210 |
severe acute | 210 |
versus host | 208 |
myeloablative conditioning | 207 |
nervous system | 207 |
organ dysfunction | 204 |
data suggest | 203 |
ml min | 202 |
old male | 200 |
autologous stem | 200 |
pediatric patients | 199 |
one year | 198 |
blood bank | 198 |
heart failure | 198 |
informed consent | 198 |
intravenous drip | 198 |
trauma patients | 196 |
intracranial pressure | 196 |
ventilated patients | 196 |
time points | 195 |
grade ii | 195 |
brain death | 194 |
cd cell | 194 |
mean arterial | 193 |
antibiotic therapy | 193 |
high mortality | 193 |
critical illness | 192 |
year period | 192 |
tidal volume | 191 |
differential diagnosis | 190 |
replacement therapy | 190 |
medical records | 188 |
related mortality | 186 |
mortality rates | 186 |
reactive protein | 186 |
survival rate | 186 |
renal function | 186 |
first hours | 185 |
myeloid leukemia | 184 |
seven patients | 183 |
hospital discharge | 183 |
renal replacement | 183 |
clinical outcomes | 182 |
clinical practice | 181 |
icu mortality | 180 |
laparoscopic approach | 180 |
acute myeloid | 179 |
mononuclear cells | 179 |
acute phase | 178 |
age years | 178 |
kidney injury | 178 |
six patients | 178 |
single center | 177 |
statistical significance | 177 |
gene expression | 177 |
well tolerated | 177 |
cell transplant | 176 |
day post | 176 |
blood glucose | 175 |
month period | 175 |
acquired pneumonia | 175 |
hearing loss | 173 |
one case | 173 |
per day | 172 |
lymph node | 172 |
grade iii | 171 |
functional outcome | 171 |
computed tomography | 170 |
glasgow coma | 170 |
saps ii | 170 |
cell count | 170 |
reduced intensity | 168 |
significantly reduced | 168 |
independently associated | 166 |
mg ml | 165 |
blood transfusion | 164 |
acute kidney | 164 |
laparoscopic surgery | 164 |
central nervous | 164 |
intracerebral hemorrhage | 163 |
donor chimerism | 163 |
intensity conditioning | 162 |
respiratory syndrome | 162 |
nitric oxide | 161 |
adverse effects | 161 |
matched unrelated | 161 |
conditioning regimens | 161 |
elderly patients | 160 |
old female | 160 |
virus infection | 159 |
spinal cord | 159 |
blood gas | 159 |
pulmonary artery | 158 |
infectious diseases | 155 |
relapse mortality | 155 |
analysis showed | 155 |
therapeutic hypothermia | 155 |
odds ratio | 155 |
oxygen saturation | 154 |
prospective observational | 154 |
left ventricular | 154 |
eight patients | 154 |
plasma levels | 154 |
determine whether | 153 |
infectious complications | 151 |
clinical data | 151 |
endothelial cells | 151 |
unrelated donors | 151 |
patient died | 151 |
nine patients | 151 |
respiratory rate | 151 |
cerebral edema | 151 |
median number | 150 |
marrow transplantation | 149 |
average age | 149 |
analyzed using | 149 |
patients showed | 148 |
fi rst | 148 |
year os | 148 |
postoperative day | 148 |
immune system | 148 |
surgical intervention | 146 |
acute leukemia | 146 |
group i | 146 |
animal models | 146 |
previous studies | 145 |
rift valley | 145 |
confidence interval | 145 |
acute lung | 145 |
patients aged | 144 |
valley fever | 144 |
may lead | 144 |
results findings | 144 |
significantly decreased | 143 |
blood products | 143 |
ex vivo | 143 |
predictive value | 143 |
retrospectively analyzed | 142 |
signifi cantly | 142 |
mm hg | 141 |
poor prognosis | 141 |
associated pneumonia | 141 |
exclusion criteria | 141 |
clinical course | 140 |
liver transplantation | 140 |
cell source | 140 |
controlled trial | 140 |
blood donors | 140 |
acute renal | 140 |
signifi cant | 140 |
months post | 140 |
old man | 139 |
myocardial infarction | 138 |
response rate | 138 |
viral load | 138 |
days later | 138 |
design methods | 138 |
chart review | 138 |
risk patients | 137 |
acute graft | 137 |
commonly used | 137 |
red cell | 137 |
retrospective cohort | 137 |
mg day | 136 |
cell lymphoma | 136 |
two cases | 136 |
hematopoietic cell | 136 |
cardiac index | 135 |
physical examination | 134 |
doc id | 134 |
old woman | 134 |
important role | 134 |
cord uid | 134 |
measured using | 134 |
clinical outcome | 134 |
prognostic factors | 133 |
health care | 133 |
necrosis factor | 133 |
blood cultures | 133 |
icu discharge | 133 |
total number | 133 |
patient developed | 132 |
sample size | 132 |
postoperative complications | 132 |
preliminary results | 132 |
median duration | 132 |
antimicrobial drugs | 131 |
airway pressure | 130 |
medical history | 130 |
patients presented | 130 |
type i | 129 |
patients requiring | 129 |
three groups | 129 |
standard deviation | 129 |
randomized controlled | 129 |
clinical characteristics | 129 |
may occur | 128 |
serum levels | 128 |
operative time | 128 |
per patient | 128 |
disease status | 128 |
surgical patients | 127 |
disease progression | 127 |
patient population | 126 |
collected data | 126 |
coma scale | 126 |
underlying disease | 126 |
positive cells | 125 |
cardiogenic shock | 125 |
higher mortality | 125 |
increased mortality | 125 |
previously reported | 125 |
surgical treatment | 124 |
white blood | 124 |
bile duct | 124 |
data collection | 124 |
dose chemotherapy | 123 |
pilot study | 123 |
one hundred | 123 |
immune reconstitution | 123 |
postoperative period | 123 |
study included | 123 |
kg min | 121 |
significant reduction | 121 |
severe tbi | 121 |
significant decrease | 121 |
growth factor | 120 |
combination therapy | 120 |
gastric cancer | 120 |
cell death | 119 |
significant correlation | 119 |
urinary tract | 119 |
normal range | 119 |
linear regression | 119 |
blood center | 119 |
acute lymphoblastic | 119 |
case series | 118 |
treatment group | 118 |
intracranial hemorrhage | 118 |
acute ischemic | 118 |
study group | 118 |
liver disease | 118 |
gas exchange | 118 |
patients presenting | 118 |
immune responses | 118 |
hematological malignancies | 117 |
viral infection | 117 |
lactate levels | 117 |
platelet engraftment | 117 |
high levels | 117 |
symptom onset | 117 |
overall mortality | 117 |
healthy volunteers | 117 |
assessed using | 117 |
ards patients | 116 |
good outcome | 116 |
enteral nutrition | 116 |
independent risk | 116 |
body temperature | 116 |
diabetes mellitus | 116 |
study aimed | 115 |
blood group | 115 |
three days | 115 |
treated patients | 114 |
may help | 114 |
patients required | 114 |
cells kg | 114 |
neutrophil engraftment | 114 |
regression model | 114 |
total body | 114 |
tumor necrosis | 114 |
ten patients | 113 |
oxidative stress | 113 |
patients suffering | 113 |
low dose | 113 |
serum samples | 112 |
systematic review | 112 |
higher risk | 112 |
invasive ventilation | 112 |
last years | 112 |
baseline characteristics | 112 |
body mass | 112 |
lymphoblastic leukemia | 112 |
blood volume | 111 |
cell dose | 110 |
coronary artery | 110 |
two different | 110 |
clinically significant | 110 |
patient care | 110 |
respiratory disease | 110 |
neurological outcome | 110 |
serum creatinine | 109 |
hcv rna | 109 |
primary endpoint | 109 |
pulmonary disease | 109 |
retrospective review | 108 |
copies ml | 108 |
brain tissue | 108 |
retrospectively reviewed | 108 |
hospital admission | 108 |
care patients | 108 |
grade i | 108 |
may result | 108 |
gastrointestinal tract | 107 |
time point | 107 |
pts received | 107 |
liver failure | 107 |
prospectively collected | 107 |
demographic data | 106 |
aneurysmal subarachnoid | 106 |
interquartile range | 106 |
tbi patients | 106 |
matched sibling | 106 |
widely used | 105 |
patient safety | 105 |
results indicate | 105 |
icu length | 105 |
year overall | 105 |
transplant recipients | 104 |
patients transplanted | 104 |
group ii | 104 |
patients included | 104 |
cell lines | 104 |
consecutive days | 104 |
atrial fibrillation | 104 |
viral infections | 103 |
cmv infection | 103 |
blood gases | 103 |
matched related | 103 |
healthy controls | 103 |
pressure support | 103 |
first time | 102 |
liver function | 102 |
mycophenolate mofetil | 102 |
every hours | 102 |
treatment option | 102 |
acute pancreatitis | 102 |
healthy donors | 101 |
two days | 101 |
public health | 101 |
family members | 101 |
chain reaction | 101 |
clinical symptoms | 101 |
first dose | 101 |
hospital length | 100 |
aplastic anemia | 100 |
endotracheal tube | 100 |
ethics committee | 100 |
cd ra | 100 |
patient received | 99 |
higher incidence | 99 |
nk cell | 99 |
head injury | 99 |
tract infection | 99 |
pulmonary edema | 98 |
fio ratio | 98 |
cancer patients | 98 |
polymerase chain | 98 |
mixed chimerism | 98 |
complete response | 97 |
rectal cancer | 97 |
stroke patients | 97 |
sibling donor | 97 |
hematologic malignancies | 97 |
incubation period | 97 |
retrospective chart | 97 |
treatment groups | 96 |
hodgkin lymphoma | 96 |
cerebral blood | 96 |
may contribute | 96 |
surgical procedures | 96 |
per year | 95 |
clinical studies | 95 |
scoring system | 95 |
patient outcomes | 95 |
significant improvement | 95 |
cerebral ischemia | 95 |
severe ards | 95 |
common cause | 94 |
acute appendicitis | 94 |
white matter | 94 |
spontaneous breathing | 94 |
mean duration | 94 |
analysis revealed | 94 |
hsct recipients | 94 |
pediatric intensive | 94 |
patients may | 94 |
patient characteristics | 94 |
hospitalized patients | 94 |
one week | 93 |
membrane oxygenation | 93 |
small intestine | 93 |
pulmonary hypertension | 93 |
acute brain | 93 |
haploidentical donor | 93 |
two weeks | 93 |
early diagnosis | 93 |
progressive disease | 93 |
pulmonary embolism | 93 |
post transplant | 93 |
aspiration pneumonia | 93 |
patients hospitalized | 93 |
died due | 92 |
parenteral nutrition | 92 |
resistant bacteria | 92 |
patients will | 92 |
shock patients | 92 |
animal model | 92 |
head ct | 92 |
may provide | 91 |
mean time | 91 |
tertiary care | 91 |
leading cause | 91 |
ejection fraction | 91 |
invasive mechanical | 91 |
twice daily | 91 |
commercially available | 91 |
patients experienced | 90 |
study shows | 90 |
high morbidity | 90 |
time period | 90 |
clinical features | 90 |
fl uid | 90 |
clinically relevant | 90 |
study population | 90 |
decision making | 90 |
blood culture | 90 |
high incidence | 90 |
hernia repair | 90 |
respiratory system | 90 |
care medicine | 90 |
continuous infusion | 89 |
blood components | 89 |
growth factors | 89 |
general surgery | 89 |
supportive care | 89 |
prospective studies | 89 |
compared using | 89 |
cell depletion | 89 |
sore throat | 89 |
antimicrobial drug | 89 |
amino acids | 89 |
teaching hospital | 89 |
partial response | 89 |
medical icu | 89 |
day compared | 89 |
major cause | 89 |
data collected | 89 |
hemorrhagic shock | 89 |
respiratory syncytial | 89 |
calculated using | 89 |
patient underwent | 88 |
pseudomonas aeruginosa | 88 |
gastric bypass | 88 |
antibiotic treatment | 88 |
extracorporeal membrane | 88 |
bacterial infections | 88 |
venous blood | 88 |
systemic inflammatory | 88 |
causative microorganisms | 88 |
oxygen delivery | 88 |
prospective cohort | 88 |
haematopoietic stem | 88 |
staphylococcus aureus | 88 |
plasma concentrations | 88 |
survival rates | 87 |
mg twice | 87 |
surgical procedure | 87 |
general anesthesia | 87 |
exact test | 87 |
first line | 87 |
even though | 87 |
findings suggest | 87 |
real time | 87 |
bacterial infection | 87 |
roc curve | 87 |
epithelial cells | 87 |
surface area | 86 |
mass index | 86 |
one month | 86 |
hemodynamic parameters | 86 |
current study | 86 |
may improve | 86 |
related complications | 86 |
antioxidant activity | 86 |
monoclonal antibodies | 86 |
age group | 86 |
cerebrospinal fluid | 85 |
cell proliferation | 85 |
significantly improved | 85 |
hospital cardiac | 85 |
phase ii | 85 |
recent years | 85 |
gold standard | 85 |
magnetic resonance | 85 |
rbc units | 85 |
nosocomial infections | 85 |
urine output | 85 |
receiver operating | 85 |
modified rankin | 85 |
significant changes | 84 |
aml patients | 84 |
selected patients | 84 |
partial remission | 84 |
blood mononuclear | 84 |
chronic graft | 84 |
recent studies | 84 |
phase i | 84 |
small bowel | 84 |
blood product | 84 |
body irradiation | 84 |
vascular resistance | 84 |
syncytial virus | 84 |
three months | 84 |
pleural effusion | 83 |
operation time | 83 |
ventilatory support | 83 |
hours post | 83 |
abdominal wall | 83 |
amino acid | 83 |
independent predictor | 83 |
infected animals | 83 |
emergency room | 83 |
results showed | 83 |
cell therapy | 83 |
remaining patients | 83 |
six months | 83 |
evaluated using | 83 |
infected patients | 83 |
increased significantly | 82 |
intracranial hypertension | 82 |
male patients | 82 |
lower respiratory | 82 |
fever virus | 82 |
heart disease | 82 |
short term | 82 |
patients diagnosed | 82 |
severity score | 82 |
plasma samples | 82 |
may cause | 82 |
novel coronavirus | 82 |
prognostic value | 82 |
single dose | 82 |
metabolic acidosis | 81 |
venous catheter | 81 |
immunosuppressive therapy | 81 |
group compared | 81 |
systolic blood | 81 |
secondary outcomes | 81 |
previously described | 81 |
identified patients | 81 |
stroke volume | 81 |
transfusion medicine | 80 |
chronic hepatitis | 80 |
rbc transfusion | 80 |
age groups | 80 |
residual disease | 80 |
stimulating factor | 80 |
trend towards | 80 |
two years | 80 |
one patients | 79 |
study showed | 79 |
first year | 79 |
umbilical cord | 79 |
myelodysplastic syndrome | 79 |
results show | 79 |
obese patients | 79 |
term outcomes | 79 |
medical record | 79 |
placebo group | 79 |
clinical study | 79 |
fluid balance | 79 |
laparoscopic cholecystectomy | 79 |
icu los | 79 |
electronic medical | 79 |
groups according | 79 |
type ii | 79 |
disease free | 79 |
cerebral perfusion | 79 |
monoclonal antibody | 78 |
study aims | 78 |
infected mice | 78 |
multiple sclerosis | 78 |
correlation coefficient | 78 |
time pcr | 78 |
three times | 78 |
surgical icu | 78 |
copyright holder | 78 |
severe traumatic | 78 |
effective treatment | 78 |
average time | 78 |
platelet counts | 78 |
significant association | 78 |
ich patients | 77 |
see table | 77 |
ct scans | 77 |
patient presented | 77 |
investigate whether | 77 |
inflammatory cytokines | 77 |
author funder | 77 |
granted medrxiv | 77 |
injury severity | 77 |
fluid responsiveness | 76 |
version posted | 76 |
risk group | 76 |
diff erence | 76 |
coronavirus disease | 76 |
cerebral artery | 76 |
three different | 76 |
progenitor cells | 76 |
clinical presentation | 76 |
term survival | 76 |
mrna expression | 76 |
right ventricular | 76 |
fluid resuscitation | 76 |
abdominal surgery | 75 |
sex ratio | 75 |
year survival | 75 |
tract infections | 75 |
convalescent plasma | 75 |
female patients | 75 |
mcg kg | 75 |
term outcome | 75 |
quality control | 75 |
cell line | 75 |
hypertonic saline | 75 |
wound healing | 75 |
invasive surgery | 75 |
mm patients | 75 |
related donor | 75 |
determined using | 74 |
fungal infection | 74 |
months later | 74 |
small number | 74 |
donor type | 74 |
food intake | 74 |
relapsed refractory | 74 |
significantly correlated | 74 |
induction therapy | 74 |
identical sibling | 74 |
clinical improvement | 74 |
syndrome coronavirus | 74 |
significantly better | 74 |
sleeve gastrectomy | 73 |
serious adverse | 73 |
well known | 73 |
iv acute | 73 |
mouse model | 73 |
smooth muscle | 73 |
transplant related | 73 |
based conditioning | 73 |
throat lozenges | 73 |
including patients | 73 |
transplant cyclophosphamide | 73 |
randomly assigned | 73 |
term follow | 73 |
preliminary data | 73 |
full donor | 73 |
normal saline | 73 |
glasgow outcome | 72 |
patients achieved | 72 |
kidney disease | 72 |
mesenchymal stem | 72 |
internal medicine | 72 |
general hospital | 72 |
analysis using | 72 |
life support | 72 |
study conducted | 72 |
line therapy | 72 |
control groups | 72 |
room temperature | 72 |
differ significantly | 72 |
protective effect | 71 |
may play | 71 |
higher rate | 71 |
trauma center | 71 |
research complications | 71 |
future studies | 71 |
red cells | 71 |
prone position | 71 |
results demonstrate | 71 |
made available | 71 |
adverse event | 71 |
disease relapse | 71 |
multivariate logistic | 71 |
median cd | 71 |
sickle cell | 71 |
skeletal muscle | 71 |
within months | 71 |
fatty acids | 71 |
observation period | 70 |
chronic obstructive | 70 |
cell depleted | 70 |
second group | 70 |
higher levels | 70 |
study suggests | 70 |
sos vod | 70 |
class i | 70 |
male patient | 70 |
indocyanine green | 70 |
delayed cerebral | 70 |
first week | 70 |
declare background | 69 |
mean values | 69 |
flow rate | 69 |
studied patients | 69 |
iu ml | 69 |
fungal infections | 69 |
transplanted patients | 69 |
medical university | 69 |
significant risk | 69 |
allogeneic sct | 69 |
kg body | 69 |
endotracheal intubation | 69 |
data analysis | 69 |
disease severity | 69 |
birth weight | 69 |
prophylaxis consisted | 69 |
middle east | 69 |
rank test | 68 |
plasma exchange | 68 |
response rates | 68 |
dcba throat | 68 |
invasive fungal | 68 |
graft rejection | 68 |
days prior | 68 |
less likely | 68 |
median days | 68 |
quality improvement | 68 |
adhesion molecules | 68 |
fold increase | 68 |
line treatment | 67 |
last follow | 67 |
days following | 67 |
outcome scale | 67 |
poor outcomes | 67 |
organ donation | 67 |
tissue oxygenation | 67 |
randomized trial | 67 |
medical treatment | 67 |
venous pressure | 67 |
oxygen therapy | 67 |
pulmonary vascular | 67 |
significant impact | 67 |
discharged home | 67 |
controlled trials | 67 |
also observed | 67 |
low risk | 67 |
gvhd grade | 67 |
will also | 66 |
kg bw | 66 |
positive correlation | 66 |
mental status | 66 |
case reports | 66 |
first months | 66 |
carotid artery | 66 |
multivariable analysis | 66 |
colorectal cancer | 66 |
older patients | 66 |
frequently used | 66 |
relapse rate | 66 |
patient age | 66 |
vital signs | 66 |
developed acute | 66 |
sah patients | 66 |
jugular vein | 66 |
hemolytic anemia | 66 |
cytokine production | 66 |
creatinine clearance | 66 |
beneficial effect | 66 |
many patients | 66 |
peer review | 65 |
curative treatment | 65 |
prone positioning | 65 |
decreased significantly | 65 |
general population | 65 |
refractory status | 65 |
external ventricular | 65 |
abdominal cavity | 65 |
escherichia coli | 65 |
obstructive pulmonary | 65 |
transfusion service | 65 |
infectious disease | 65 |
gram negative | 65 |
days vs | 65 |
retrospective observational | 65 |
nursing staff | 65 |
showed significant | 65 |
platelet recovery | 65 |
marrow transplant | 65 |
conservative treatment | 65 |
cell surface | 65 |
severity scores | 65 |
center study | 64 |
diff erent | 64 |
enteral feeding | 64 |
eff ect | 64 |
cox regression | 64 |
middle cerebral | 64 |
primary objective | 64 |
learning curve | 64 |
hemodynamic instability | 64 |
allogeneic transplantation | 64 |
cell disease | 63 |
east respiratory | 63 |
postoperative course | 63 |
carbon dioxide | 63 |
one day | 63 |
donor lymphocyte | 63 |
cardiac function | 63 |
natural killer | 63 |
group received | 63 |
common complication | 63 |
salvage therapy | 63 |
female patient | 63 |
head trauma | 63 |
oxygen consumption | 63 |
data indicate | 63 |
square test | 63 |
one hour | 63 |
high prevalence | 62 |
liver resection | 62 |
transfusion reactions | 62 |
patients whose | 62 |
active disease | 62 |
ich score | 62 |
statistical difference | 62 |
dorsal funiculus | 62 |
body surface | 62 |
seven days | 62 |
negative bacteria | 62 |
disease control | 62 |
aged years | 62 |
hla matched | 62 |
cell counts | 62 |
surgical technique | 62 |
high doses | 62 |
considered significant | 62 |
predictive factors | 62 |
high frequency | 62 |
arrest patients | 62 |
cd expression | 62 |
medical care | 61 |
success rate | 61 |
controlled study | 61 |
first case | 61 |
acute physiology | 61 |
rankin scale | 61 |
may increase | 61 |
study will | 61 |
minimal residual | 61 |
medical intensive | 61 |
resonance imaging | 61 |
study including | 61 |
negative predictive | 61 |
main cause | 61 |
myeloma patients | 61 |
expiratory pressure | 61 |
complement activation | 61 |
relapse incidence | 61 |
vena cava | 61 |
temperature management | 61 |
serum concentrations | 61 |
patient outcome | 60 |
autologous hsct | 60 |
hospital day | 60 |
lymphoma patients | 60 |
within minutes | 60 |
acute stroke | 60 |
limited data | 60 |
injured patients | 60 |
well established | 60 |
massive transfusion | 60 |
necropsy findings | 60 |
colony stimulating | 60 |
serum sodium | 59 |
blood donor | 59 |
interim analysis | 59 |
prospective randomized | 59 |
time course | 59 |
burst suppression | 59 |
cardiopulmonary bypass | 59 |
lymphocyte count | 59 |
healthy subjects | 59 |
cd count | 59 |
operating room | 59 |
randomized clinical | 59 |
upper respiratory | 59 |
treated group | 59 |
assess whether | 59 |
emergency surgery | 59 |
identify patients | 59 |
malignant disease | 59 |
also significantly | 59 |
several studies | 59 |
glucose levels | 59 |
blood count | 59 |
results obtained | 59 |
lung disease | 59 |
operating characteristic | 59 |
clinical manifestations | 59 |
remains unclear | 59 |
node dissection | 59 |
autologous hematopoietic | 59 |
flow cytometric | 59 |
way anova | 59 |
portal vein | 59 |
may develop | 58 |
laboratory tests | 58 |
early phase | 58 |
laboratory data | 58 |
large number | 58 |
mesenteric lymph | 58 |
early post | 58 |
test results | 58 |
cytokine release | 58 |
safety profile | 58 |
haploidentical transplantation | 58 |
post hoc | 58 |
surgery patients | 57 |
blood lactate | 57 |
renal dysfunction | 57 |
regression models | 57 |
table shows | 57 |
nosocomial infection | 57 |
occlusive disease | 57 |
whitney test | 57 |
newly diagnosed | 57 |
mean number | 57 |
positive patients | 57 |
postoperative pain | 57 |
university medical | 57 |
breast cancer | 57 |
many cases | 57 |
upper gi | 57 |
liver injury | 57 |
underwent allogeneic | 57 |
fatty acid | 57 |
drug therapy | 57 |
multicenter study | 57 |
solid tumors | 57 |
may reduce | 57 |
nutritional support | 57 |
inflammatory mediators | 57 |
data regarding | 57 |
dendritic cells | 57 |
enrolled patients | 56 |
major surgery | 56 |
circulatory failure | 56 |
also found | 56 |
early stage | 56 |
midline shift | 56 |
hcv infection | 56 |
median os | 56 |
artery bypass | 56 |
lung cancer | 56 |
influenza virus | 56 |
colon cancer | 56 |
soft tissue | 56 |
healthy dogs | 56 |
blood supply | 56 |
eligible patients | 56 |
eleven patients | 56 |
serum albumin | 56 |
organ damage | 56 |
time spent | 56 |
graft function | 56 |
independent predictors | 56 |
cell responses | 56 |
twelve patients | 55 |
high rate | 55 |
severe disease | 55 |
cell viability | 55 |
multivariable logistic | 55 |
medical patients | 55 |
mean apache | 55 |
weight gain | 55 |
vs days | 55 |
defi ned | 55 |
high level | 55 |
intravenous injection | 55 |
response syndrome | 55 |
positive predictive | 55 |
trial registry | 55 |
burn patients | 55 |
immune function | 55 |
steady state | 55 |
hemorrhagic cystitis | 55 |
per week | 55 |
blood transfusions | 55 |
undergoing allogeneic | 55 |
patients suffered | 55 |
severe chronic | 55 |
perfusion pressure | 55 |
pregnant women | 55 |
five days | 55 |
cytokine storm | 55 |
may represent | 55 |
acute myocardial | 55 |
allogeneic hct | 55 |
chronic kidney | 55 |
secondary endpoints | 55 |
significantly elevated | 55 |
bronchoalveolar lavage | 55 |
reperfusion injury | 54 |
sensorineural hearing | 54 |
significantly greater | 54 |
loading dose | 54 |
median length | 54 |
older age | 54 |
clinical response | 54 |
functional outcomes | 54 |
ebv reactivation | 54 |
atg group | 54 |
survival time | 54 |
standard treatment | 54 |
prognostic factor | 54 |
randomized study | 54 |
first group | 54 |
wound infection | 54 |
normal values | 54 |
chest pain | 54 |
tidal volumes | 54 |
underwent laparoscopic | 54 |
severe cases | 54 |
antibody screen | 54 |
international congresses | 54 |
rhce ce | 54 |
outcome measures | 54 |
data show | 54 |
multiorgan failure | 54 |
antithymocyte globulin | 54 |
data will | 54 |
descriptive statistics | 54 |
life threatening | 54 |
lps injection | 53 |
patients enrolled | 53 |
early postoperative | 53 |
underwent hsct | 53 |
patients following | 53 |
without significant | 53 |
neurologic outcome | 53 |
major epidemic | 53 |
supine position | 53 |
patients engrafted | 53 |
still alive | 53 |
studies suggest | 53 |
frozen plasma | 53 |
clinical condition | 53 |
new york | 53 |
years ago | 53 |
clinical disease | 53 |
therapeutic option | 53 |
continuous variables | 53 |
identifi ed | 53 |
investigated whether | 53 |
immune cells | 53 |
early detection | 53 |
western blot | 53 |
analysed using | 53 |
kg times | 53 |
propensity score | 52 |
comatose patients | 52 |
improved survival | 52 |
diagnostic criteria | 52 |
total protein | 52 |
group vs | 52 |
successfully treated | 52 |
evaluate whether | 52 |
study demonstrates | 52 |
lung tissue | 52 |
fludarabine mg | 52 |
median day | 52 |
foreign body | 52 |
lung function | 52 |
united kingdom | 52 |
antimicrobial therapy | 52 |
plasma concentration | 52 |
liquid chromatography | 52 |
operative day | 52 |
systolic function | 52 |
performance status | 52 |
mean length | 52 |
cell types | 52 |
sofa scores | 52 |
confidence intervals | 52 |
control study | 52 |
molecular weight | 52 |
liver cirrhosis | 52 |
wide range | 52 |
positive results | 52 |
mean value | 52 |
tissue oxygen | 52 |
spontaneous circulation | 52 |
mean follow | 52 |
graft source | 51 |
hematoma expansion | 51 |
support ventilation | 51 |
patient showed | 51 |
center experience | 51 |
robotic surgery | 51 |
small sample | 51 |
secondary bacterial | 51 |
blood donation | 51 |
clinical examination | 51 |
least days | 51 |
initial treatment | 51 |
month follow | 51 |
acute exacerbation | 51 |
remained unchanged | 51 |
significantly longer | 51 |
positive samples | 51 |
hours later | 51 |
clinical diagnosis | 51 |
fluid administration | 51 |
often used | 51 |
affected animals | 51 |
patients compared | 51 |
significant morbidity | 51 |
posted october | 51 |
icu admissions | 51 |
respiratory mechanics | 51 |
definitive diagnosis | 51 |
neutrophil recovery | 51 |
grade iv | 51 |
pain relief | 51 |
single centre | 51 |
hazard ratio | 51 |
asah patients | 50 |
liver enzymes | 50 |
second day | 50 |
per group | 50 |
copd patients | 50 |
patients years | 50 |
previously published | 50 |
observational cohort | 50 |
palliative care | 50 |
may reflect | 50 |
vaccinated animals | 50 |
red cross | 50 |
innate immune | 50 |
endothelial cell | 50 |
using two | 50 |
study groups | 50 |
burn injury | 50 |
vein thrombosis | 50 |
younger patients | 50 |
died within | 50 |
cardiopulmonary resuscitation | 50 |
partial pressure | 50 |
coma score | 50 |
tissue damage | 50 |
false positive | 50 |
broad spectrum | 50 |
jugular bulb | 50 |
liver fibrosis | 50 |
mismatched unrelated | 50 |
first three | 49 |
failure assessment | 49 |
fresh frozen | 49 |
research support | 49 |
anastomotic leak | 49 |
worse outcomes | 49 |
antifungal prophylaxis | 49 |
extubation failure | 49 |
autologous transplantation | 49 |
colorectal surgery | 49 |
iv agvhd | 49 |
comorbidity index | 49 |
disseminated intravascular | 49 |
severe infections | 49 |
oral administration | 49 |
haploidentical donors | 49 |
eff ects | 49 |
bacterial pneumonia | 49 |
transplant patients | 49 |
underwent allo | 49 |
transcranial doppler | 49 |
two months | 49 |
catheter removal | 49 |
ill children | 49 |
haploidentical hsct | 49 |
functional status | 49 |
patients using | 49 |
multiple trauma | 49 |
electron microscopy | 48 |
thymocyte globulin | 48 |
control patients | 48 |
treatment options | 48 |
sibling donors | 48 |
fecal samples | 48 |
progression free | 48 |
three cases | 48 |
sodium chloride | 48 |
low incidence | 48 |
bowel obstruction | 48 |
patients submitted | 48 |
three years | 48 |
neuro icu | 48 |
study protocol | 48 |
better outcome | 48 |
regimen consisted | 48 |
cd kg | 48 |
function tests | 48 |
positive blood | 48 |
group showed | 48 |
hct recipients | 48 |
serious complication | 48 |
extensive chronic | 48 |
high titer | 48 |
chest wall | 48 |
bovine viral | 48 |
intravascular coagulation | 48 |
four groups | 48 |
treatment period | 48 |
patient groups | 48 |
internal jugular | 48 |
wistar rats | 48 |
published data | 48 |
gas analysis | 48 |
overall response | 48 |
mainly due | 48 |
unfavorable outcome | 47 |
longer duration | 47 |
ct head | 47 |
first study | 47 |
bariatric surgery | 47 |
remained stable | 47 |
world health | 47 |
intraventricular hemorrhage | 47 |
patient group | 47 |
may benefit | 47 |
per kg | 47 |
cell activation | 47 |
low levels | 47 |
open surgery | 47 |
also associated | 47 |
general icu | 47 |
systemic inflammation | 47 |
similar results | 47 |
animals may | 47 |
poorly understood | 47 |
average number | 47 |
health status | 47 |
host defense | 47 |
study drug | 47 |
primary graft | 47 |
academic medical | 47 |
probably due | 47 |
immunocompromised patients | 47 |
rabies virus | 47 |
hoc analysis | 47 |
analyzed patients | 47 |
different types | 47 |
complication rate | 47 |
sequential organ | 47 |
infected cells | 47 |
ich volume | 47 |
drug administration | 47 |
animals will | 47 |
venous thromboembolism | 47 |
reactive oxygen | 47 |
fl ow | 46 |
took place | 46 |
patients survived | 46 |
clinical findings | 46 |
every patient | 46 |
consecutive adult | 46 |
tested positive | 46 |
matched donor | 46 |
developed grade | 46 |
viral loads | 46 |
refractory disease | 46 |
cell subsets | 46 |
median dose | 46 |
invasive approach | 46 |
beneficial effects | 46 |
rbc transfusions | 46 |
respiratory symptoms | 46 |
center background | 46 |
west nile | 46 |
major complications | 46 |
cell culture | 46 |
cytokine levels | 46 |
significantly less | 46 |
post hsct | 46 |
second line | 46 |
respiratory support | 46 |
five years | 46 |
surg endosc | 46 |
significant change | 46 |
study intervention | 46 |
patient demographics | 46 |
cyclophosphamide mg | 46 |
examination revealed | 46 |
past medical | 46 |
invasive aspergillosis | 46 |
also used | 46 |
risk assessment | 45 |
also performed | 45 |
adipose tissue | 45 |
good results | 45 |
peripheral stem | 45 |
recombinant human | 45 |
left side | 45 |
tumor cells | 45 |
gestational age | 45 |
lipid peroxidation | 45 |
also showed | 45 |
congestive heart | 45 |
major bleeding | 45 |
may require | 45 |
adhesion molecule | 45 |
frequent complication | 45 |
elevated icp | 45 |
solid organ | 45 |
requiring mechanical | 45 |
statistically different | 45 |
using standard | 45 |
four days | 45 |
old patient | 45 |
laboratory findings | 45 |
wild type | 45 |
guinea pigs | 45 |
marrow failure | 45 |
twenty patients | 45 |
written informed | 45 |
received either | 45 |
hiatal hernia | 45 |
health system | 45 |
immunosorbent assay | 45 |
patients met | 45 |
diff erences | 45 |
improve survival | 45 |
intervention group | 45 |
conversion rate | 45 |
clinical significance | 45 |
severe head | 45 |
bile ducts | 45 |
non invasive | 45 |
outcome data | 45 |
group patients | 45 |
first two | 45 |
authors declare | 45 |
kg cd | 45 |
treatment modality | 45 |
cell collection | 45 |
naturally occurring | 45 |
cirrhotic patients | 44 |
positive end | 44 |
steroid therapy | 44 |
icp monitoring | 44 |
central line | 44 |
emergency medicine | 44 |
cell mobilization | 44 |
mcg ml | 44 |
undergoing hsct | 44 |
mast cell | 44 |
within normal | 44 |
cox proportional | 44 |
complete blood | 44 |
strongly associated | 44 |
median survival | 44 |
granulocyte colony | 44 |
renal disease | 44 |
platelet aggregation | 44 |
lung transplantation | 44 |
international license | 44 |
within weeks | 44 |
oligodendroglial cell | 44 |
stage iii | 44 |
retrospectively evaluated | 44 |
artery catheter | 44 |
melphalan mg | 44 |
proinflammatory cytokines | 44 |
therapeutic intervention | 44 |
neutrophil count | 44 |
surgical approach | 44 |
patient cohort | 44 |
receptor antagonist | 44 |
antiviral therapy | 44 |
acute care | 44 |
antibody titers | 44 |
kg dose | 44 |
health organization | 44 |
first reported | 44 |
renal impairment | 44 |
postoperative morbidity | 44 |
vast majority | 44 |
negative correlation | 44 |
skin lesions | 44 |
differential diagnoses | 44 |
ravulizumab bsc | 44 |
developed severe | 44 |
right heart | 43 |
i ii | 43 |
per cent | 43 |
arterial hypertension | 43 |
rhesus macaques | 43 |
abo rh | 43 |
post operative | 43 |
anastomotic leakage | 43 |
pathogen reduction | 43 |
examination showed | 43 |
intravenous infusion | 43 |
hla identical | 43 |
refractory acute | 43 |
main causes | 43 |
subgroup analysis | 43 |
baseline values | 43 |
class ii | 43 |
chi square | 43 |
auf die | 43 |
emergency departments | 43 |
extracorporeal photopheresis | 43 |
autologous peripheral | 43 |
corticosteroid therapy | 43 |
control animals | 43 |
group iii | 43 |
increased levels | 43 |
lower incidence | 43 |
outcome measure | 43 |
hand hygiene | 43 |
prolonged mechanical | 43 |
intubated patients | 43 |
surgical intensive | 43 |
therapeutic approach | 43 |
blood levels | 43 |
left ventricle | 43 |
surgical site | 43 |
patienten mit | 43 |
experimental infection | 43 |
receive either | 43 |
year cumulative | 43 |
studies showed | 43 |
severe aplastic | 43 |
failure requiring | 43 |
required mechanical | 43 |
medrxiv preprint | 43 |
tranexamic acid | 43 |
neurological examination | 43 |
allogeneic haematopoietic | 43 |
ml vs | 43 |
cells ml | 42 |
increased morbidity | 42 |
mit einem | 42 |
body condition | 42 |
septic complications | 42 |
data obtained | 42 |
standard therapy | 42 |
spectrum antibiotics | 42 |
blood sample | 42 |
protein expression | 42 |
corpus callosum | 42 |
tissue injury | 42 |
induced lung | 42 |
fluid challenge | 42 |
trend toward | 42 |
rat model | 42 |
reference range | 42 |
laboratory parameters | 42 |
likely due | 42 |
within one | 42 |
inguinal hernia | 42 |
patient required | 42 |
acute abdomen | 42 |
free days | 42 |
repeated measures | 42 |
kg iv | 42 |
yoghurt sample | 42 |
blood centers | 42 |
heart surgery | 42 |
research funding | 42 |
mononuclear cell | 42 |
maintenance therapy | 42 |
treatment related | 42 |
patients infected | 42 |
respiratory infection | 42 |
lumbar puncture | 42 |
blood donations | 42 |
higher rates | 42 |
uric acid | 42 |
disclosure background | 42 |
severe respiratory | 42 |
th percentile | 42 |
pts died | 42 |
clinical use | 42 |
several days | 42 |
received myeloablative | 42 |
useful tool | 42 |
liver transplant | 41 |
contact tracing | 41 |
descriptive study | 41 |
hiv infection | 41 |
showed significantly | 41 |
treated animals | 41 |
haploidentical transplant | 41 |
high volume | 41 |
relative risk | 41 |
achieved cr | 41 |
early mortality | 41 |
nucleated cells | 41 |
ventricular drain | 41 |
therapeutic strategy | 41 |
vod sos | 41 |
severe trauma | 41 |
alkaline phosphatase | 41 |
event day | 41 |
end point | 41 |
serious complications | 41 |
per month | 41 |
failure due | 41 |
total dose | 41 |
center retrospective | 41 |
prospectively studied | 41 |
kg per | 41 |
plasminogen activator | 41 |
steroid treatment | 41 |
remains controversial | 41 |
severe complications | 41 |
severe cgvhd | 41 |
viral replication | 41 |
three weeks | 41 |
incisional hernia | 41 |
significantly shorter | 41 |
energy expenditure | 41 |
animal studies | 41 |
stable disease | 41 |
hepatocellular carcinoma | 41 |
nursing care | 41 |
patients affected | 41 |
two hours | 41 |
common cold | 41 |
antibiotic prophylaxis | 41 |
chronic liver | 41 |
sixteen patients | 41 |
past years | 41 |
may include | 41 |
cd positive | 41 |
literature review | 41 |
high grade | 41 |
left atrial | 41 |
mixed venous | 41 |
incidence rate | 40 |
cause mortality | 40 |
male female | 40 |
study patients | 40 |
clinical parameters | 40 |
pathologic findings | 40 |
abdominal trauma | 40 |
patient data | 40 |
prospectively enrolled | 40 |
tyrosine kinase | 40 |
family donor | 40 |
hepatic encephalopathy | 40 |
klebsiella pneumoniae | 40 |
longer follow | 40 |
infusion rate | 40 |
inflammatory cells | 40 |
insulin resistance | 40 |
immunodeficiency virus | 40 |
severe covid | 40 |
abdominal ct | 40 |
improve patient | 40 |
agvhd grade | 40 |
surgical resection | 40 |
average duration | 40 |
control mice | 40 |
severe complication | 40 |
therapeutic strategies | 40 |
drug interactions | 40 |
patients needed | 40 |
statistical analyses | 40 |
without complications | 40 |
retrospectively collected | 40 |
following parameters | 40 |
immunosuppressive treatment | 40 |
often associated | 40 |
blood type | 40 |
underlying diseases | 40 |
brain edema | 40 |
previous study | 40 |
specific cd | 40 |
ii scores | 40 |
wbc count | 40 |
respiratory infectious | 40 |
met inclusion | 40 |
mg daily | 40 |
intestinal obstruction | 40 |
excluded patients | 40 |
brain mri | 40 |
samples collected | 40 |
resource utilization | 40 |
year post | 40 |
group versus | 40 |
good clinical | 40 |
upper gastrointestinal | 40 |
mesenteric artery | 40 |
continuous eeg | 40 |
medical students | 40 |
sum test | 40 |
cancer surgery | 40 |
cant diff | 40 |
viral reactivation | 39 |
fed calves | 39 |
analysis included | 39 |
therapy may | 39 |
year mortality | 39 |
neutropenic fever | 39 |
hsct patients | 39 |
thalassemia major | 39 |
superior mesenteric | 39 |
scoring systems | 39 |
transit time | 39 |
quantitative pcr | 39 |
immune cell | 39 |
daily living | 39 |
gene therapy | 39 |
phase proteins | 39 |
age range | 39 |
sbt abpc | 39 |
care setting | 39 |
total patients | 39 |
better understand | 39 |
patient days | 39 |
related donors | 39 |
four hours | 39 |
viral rna | 39 |
oxygen species | 39 |
primary efficacy | 39 |
different levels | 39 |
guidelines recommend | 39 |
linked immunosorbent | 39 |
identified using | 39 |
retrospectively analysed | 39 |
pulmonary function | 39 |
leukemia patients | 39 |
mean hospital | 39 |
niv failure | 39 |
hemorrhagic fever | 39 |
dose dependent | 39 |
antifungal therapy | 39 |
complications occurred | 39 |
secondary outcome | 39 |
clinical experience | 39 |
donor age | 39 |
cell carcinoma | 39 |
reported case | 39 |
institutional review | 39 |
cardiac failure | 39 |
randomised controlled | 39 |
university hospitals | 39 |
factors affecting | 39 |
mean sd | 39 |
rare complication | 39 |
multidisciplinary team | 39 |
experimental group | 39 |
immune suppression | 39 |
pandemic influenza | 39 |
diffuse large | 39 |
inferior vena | 39 |
mayo clinic | 38 |
may influence | 38 |
peak hour | 38 |
clinical setting | 38 |
one dose | 38 |
hemorrhagic stroke | 38 |
routine use | 38 |
adjuvant chemotherapy | 38 |
mass spectrometry | 38 |
autoimmune diseases | 38 |
underwent asct | 38 |
pulse oximetry | 38 |
airway management | 38 |
chemotherapy followed | 38 |
favorable outcome | 38 |
mrna levels | 38 |
acute liver | 38 |
treatment strategies | 38 |
routinely used | 38 |
remains unknown | 38 |
stromal cells | 38 |
done using | 38 |
sepsis syndrome | 38 |
care society | 38 |
increasingly used | 38 |
lung volume | 38 |
may serve | 38 |
previous reports | 38 |
platelet function | 38 |
ecmo support | 38 |
different time | 38 |
review board | 38 |
surgical management | 38 |
blunt trauma | 38 |
transthoracic echocardiography | 38 |
severe pneumonia | 38 |
early identification | 38 |
blood services | 38 |
fluid therapy | 38 |
right side | 38 |
drug susceptibility | 38 |
severely ill | 38 |
chronic health | 38 |
cells per | 38 |
crp levels | 38 |
comparative study | 38 |
induction chemotherapy | 38 |
abdominal sepsis | 38 |
significant effect | 38 |
organ injury | 38 |
study demonstrated | 38 |
surviving patients | 38 |
longer time | 38 |
clinical efficacy | 38 |
meal number | 38 |
least hours | 38 |
white cell | 38 |
improve outcomes | 38 |
bei der | 38 |
systemic vascular | 38 |
lower levels | 38 |
hearing aids | 38 |
one third | 38 |
classified according | 38 |
neutralizing antibodies | 38 |
cmv disease | 38 |
treatment failure | 38 |
severe brain | 38 |
ventilator settings | 38 |
valve replacement | 38 |
graft survival | 38 |
chest tube | 38 |
volume reduction | 38 |
weeks later | 38 |
release syndrome | 37 |
cells showed | 37 |
clinical variables | 37 |
lactate level | 37 |
apheresis platelets | 37 |
haploidentical stem | 37 |
kg hr | 37 |
cutoff value | 37 |
artery disease | 37 |
expression levels | 37 |
total gastrectomy | 37 |
cerebral vasospasm | 37 |
apache iii | 37 |
cd depleted | 37 |
inflammatory responses | 37 |
ug ml | 37 |
muscle weakness | 37 |
secondary graft | 37 |
phase iii | 37 |
except one | 37 |
jazz pharmaceuticals | 37 |
adverse reactions | 37 |
autologous sct | 37 |
common bile | 37 |
day period | 37 |
thrombotic microangiopathy | 37 |
thirteen patients | 37 |
tertiary hospital | 37 |
change significantly | 37 |
may indicate | 37 |
postinoculation day | 37 |
retrospective data | 37 |
gcs score | 37 |
nutritional status | 37 |
healthy adult | 37 |
demographic characteristics | 37 |
wilcoxon rank | 37 |
categorical variables | 37 |
cell tumors | 37 |
dawley rats | 37 |
free radicals | 37 |
considered statistically | 37 |
administered intravenously | 37 |
mean difference | 37 |
cells infused | 37 |
early stages | 37 |
higher doses | 37 |
neurological recovery | 37 |
previously healthy | 37 |
new onset | 37 |
pulmonary infection | 37 |
animals infected | 37 |
patient samples | 37 |
patients relapsed | 37 |
received mg | 37 |
platelet transfusion | 37 |
day survival | 37 |
using flow | 37 |
will include | 37 |
patient survival | 37 |
patients within | 36 |
operating time | 36 |
cell population | 36 |
patient blood | 36 |
febrile neutropenia | 36 |
protein levels | 36 |
highly effective | 36 |
identify factors | 36 |
lymphocyte infusion | 36 |
cerebral infarction | 36 |
without evidence | 36 |
respiratory insufficiency | 36 |
complications related | 36 |
chronic respiratory | 36 |
third day | 36 |
endemic areas | 36 |
icu staff | 36 |
tested using | 36 |
potential risk | 36 |
national university | 36 |
autoimmune hemolytic | 36 |
multivariate analyses | 36 |
organ function | 36 |
received hsct | 36 |
genomic dna | 36 |
year follow | 36 |
fluorescence imaging | 36 |
patients randomized | 36 |
nucleic acid | 36 |
secondary objectives | 36 |
every days | 36 |
study day | 36 |
curative option | 36 |
right ventricle | 36 |
cell infusion | 36 |
bacterial translocation | 36 |
young patients | 36 |
copd exacerbation | 36 |
neurological outcomes | 36 |
congenital heart | 36 |
levels increased | 36 |
tissue samples | 36 |
malignant diseases | 36 |
host response | 36 |
entire cohort | 36 |
respiratory infections | 36 |
venous thrombosis | 36 |
advanced disease | 36 |
analysis will | 36 |
studies will | 36 |
daily dose | 36 |
th postoperative | 36 |
vasoactive drugs | 36 |
iu kg | 36 |
curative therapy | 36 |
hepatic failure | 36 |
disease course | 36 |
first month | 36 |
chronic renal | 36 |
mortality risk | 36 |
ca patients | 36 |
related toxicity | 36 |
platelet transfusions | 36 |
major role | 36 |
complete resolution | 36 |
catheter insertion | 36 |
last decade | 36 |
undergoing cardiac | 36 |
kidney function | 36 |
infection rates | 36 |
neurological complications | 36 |
cardiac disease | 36 |
cell function | 36 |
medical staff | 36 |
second patient | 35 |
troponin i | 35 |
potentially curative | 35 |
icg fluorescence | 35 |
neutropenic patients | 35 |
spontaneous ich | 35 |
group without | 35 |
dengue virus | 35 |
cell replete | 35 |
hematoma volume | 35 |
hours prior | 35 |
operative complications | 35 |
treatment duration | 35 |
major complication | 35 |
performed according | 35 |
hospital course | 35 |
salvage treatment | 35 |
mortality among | 35 |
will provide | 35 |
lactate dehydrogenase | 35 |
critical patients | 35 |
volume expansion | 35 |
risk acute | 35 |
iron deficiency | 35 |
data available | 35 |
therapeutic options | 35 |
herpes simplex | 35 |
conducted using | 35 |
meld score | 35 |
early recognition | 35 |
internal carotid | 35 |
bk virus | 35 |
blood vessels | 35 |
transplant period | 35 |
one group | 35 |
brain damage | 35 |
major abdominal | 35 |
viral diarrhea | 35 |
tissue perfusion | 35 |
increased incidence | 35 |
initial dose | 35 |
may become | 35 |
subdural hematoma | 35 |
better survival | 35 |
every day | 35 |
acinetobacter baumannii | 35 |
left lateral | 35 |
several factors | 35 |
mast cells | 35 |
international guidelines | 35 |
analyses will | 35 |
work location | 35 |
treated cells | 35 |
protective ventilation | 35 |
decompressive craniectomy | 35 |
average length | 35 |
late effects | 35 |
patients due | 35 |
least months | 35 |
venous access | 35 |
transgenic mice | 35 |
will receive | 35 |
may affect | 35 |
burned patients | 35 |
using spss | 35 |
better outcomes | 35 |
adult icu | 35 |
retrospectively studied | 35 |
medical management | 35 |
larger studies | 35 |
also evaluated | 35 |
potential therapeutic | 35 |
north america | 34 |
bacterial meningitis | 34 |
nd allo | 34 |
already published | 34 |
clinical conditions | 34 |
compartment syndrome | 34 |
years post | 34 |
lactic acid | 34 |
four times | 34 |
cell populations | 34 |
patients respectively | 34 |
selected cases | 34 |
pivotal role | 34 |
serum lactate | 34 |
pathological findings | 34 |
month mortality | 34 |
studies using | 34 |
platelet concentrates | 34 |
ko mice | 34 |
making process | 34 |
clinical benefit | 34 |
hospital los | 34 |
seventeen patients | 34 |
transplant outcomes | 34 |
missing data | 34 |
icu survivors | 34 |
acute cholecystitis | 34 |
right hemicolectomy | 34 |
packed red | 34 |
reach statistical | 34 |
statistical differences | 34 |
type diabetes | 34 |
adverse effect | 34 |
elective surgery | 34 |
control dogs | 34 |
brain barrier | 34 |
icu nurses | 34 |
financial support | 34 |
emergency medical | 34 |
hcv genotype | 34 |
hemodynamically stable | 34 |
nosocomial pneumonia | 34 |
several months | 34 |
sectional study | 34 |
mitral valve | 34 |
abstract already | 34 |
throat soreness | 34 |
effective method | 34 |
minute ventilation | 34 |
gastroesophageal reflux | 34 |
blood stream | 34 |
data set | 34 |
treated rats | 34 |
thermal injury | 34 |
also known | 34 |
primary end | 34 |
individual patients | 34 |
results will | 34 |
prothrombin time | 34 |
false negative | 34 |
side effect | 34 |
every weeks | 34 |
plateau pressure | 34 |
mit der | 34 |
normal levels | 34 |
pulmonary arterial | 34 |
new therapeutic | 34 |
infl ammatory | 34 |
infrared spectroscopy | 34 |
times per | 34 |
predict outcome | 34 |
elevated levels | 34 |
protocol amendment | 34 |
curve analysis | 34 |
care hospital | 34 |
shockable rhythm | 34 |
mean blood | 34 |
infection control | 34 |
tissue hypoxia | 34 |
urine samples | 34 |
scan showed | 33 |
may explain | 33 |
matched controls | 33 |
cik cells | 33 |
activated caspase | 33 |
tnf production | 33 |
slightly higher | 33 |
pg kg | 33 |
transverse colon | 33 |
data suggests | 33 |
evidence suggests | 33 |
related adverse | 33 |
clinical case | 33 |
cgvhd patients | 33 |
foreign bodies | 33 |
negative patients | 33 |
pulse pressure | 33 |
lozenges group | 33 |
health evaluation | 33 |
neurological status | 33 |
patients developing | 33 |
diabetic patients | 33 |
study center | 33 |
ferritin levels | 33 |
im rahmen | 33 |
signal transduction | 33 |
endothelial dysfunction | 33 |
fourteen patients | 33 |
following criteria | 33 |
time interval | 33 |
nasogastric tube | 33 |
following hsct | 33 |
least two | 33 |
lung water | 33 |
invasive procedures | 33 |
cell reconstitution | 33 |
healthcare professionals | 33 |
lavage fluid | 33 |
roc curves | 33 |
target temperature | 33 |
information system | 33 |
small animal | 33 |
results confirm | 33 |
sepsis patients | 33 |
differed significantly | 33 |
buffy coat | 33 |
serum il | 33 |
received allo | 33 |
positive airway | 33 |
organ support | 33 |
transpulmonary thermodilution | 33 |
diaphragmatic hernia | 33 |
experimental studies | 33 |
survival analysis | 33 |
cardiac dysfunction | 33 |
hospital death | 33 |
rectal temperature | 33 |
steroid refractory | 33 |
two consecutive | 33 |
retrospective case | 33 |
blood sampling | 33 |
risk score | 33 |
admitted patients | 33 |
second transplant | 33 |
murine model | 33 |
inflammatory reaction | 33 |
also compared | 33 |
specific antibodies | 33 |
significant proportion | 33 |
term results | 33 |
cardiac surgical | 33 |
bacterial contamination | 33 |
clinical deterioration | 33 |
esophageal pressure | 33 |
biliary tract | 33 |
study evaluated | 33 |
neurointensive care | 33 |
inflammatory markers | 33 |
two pts | 33 |
per minute | 33 |
gvhd occurred | 33 |
developed chronic | 33 |
surviving sepsis | 33 |
four different | 33 |
clinical evaluation | 33 |
conventional treatment | 32 |
radiation therapy | 32 |
targeted temperature | 32 |
culture system | 32 |
noninvasive ventilation | 32 |
will help | 32 |
data points | 32 |
continuous renal | 32 |
inotropic support | 32 |
pet ct | 32 |
patients reported | 32 |
short course | 32 |
complete donor | 32 |
admission gcs | 32 |
discharged alive | 32 |
inner ear | 32 |
data support | 32 |
training program | 32 |
inspiratory pressure | 32 |
available data | 32 |
clinical evidence | 32 |
median interval | 32 |
csf treatment | 32 |
days respectively | 32 |
treatment may | 32 |
locally advanced | 32 |
blood component | 32 |
included age | 32 |
complication rates | 32 |
new method | 32 |
arterial lactate | 32 |
median values | 32 |
lower risk | 32 |
hours following | 32 |
clinical effects | 32 |
nan title | 32 |
medical school | 32 |
limited number | 32 |
high flow | 32 |
mg every | 32 |
optic nerve | 32 |
specific treatment | 32 |
selection criteria | 32 |
treated mice | 32 |
confi rmed | 32 |
connective tissue | 32 |
bypass grafting | 32 |
successful treatment | 32 |
meal size | 32 |
organ transplantation | 32 |
mean icp | 32 |
dysfunction syndrome | 32 |
low level | 32 |
cystic duct | 32 |
oxygen tension | 32 |
last two | 32 |
defined according | 32 |
improve outcome | 32 |
ventricular function | 32 |
post transplantation | 32 |
lymphocyte infusions | 32 |
tracheal intubation | 32 |
better os | 32 |
months following | 32 |
level i | 32 |
first patient | 32 |
three consecutive | 32 |
european countries | 32 |
following treatment | 32 |
apache score | 32 |
ventricular fibrillation | 32 |
absolute neutrophil | 32 |
oxygenation index | 32 |
human serum | 32 |
patients operated | 32 |
liver biopsy | 32 |
ventilator associated | 32 |
blood collection | 32 |
mobilized peripheral | 32 |
gastrointestinal bleeding | 32 |
base excess | 32 |
infection rate | 32 |
clinical background | 32 |
fi ndings | 32 |
longer icu | 32 |
traumatic stress | 32 |
flow velocity | 32 |
altman analysis | 32 |
rank sum | 32 |
endovascular treatment | 32 |
following allogeneic | 32 |
xa activity | 32 |
protein synthesis | 32 |
signs include | 32 |
mri brain | 32 |
may present | 32 |
bypass surgery | 32 |
high rates | 32 |
two independent | 32 |
different groups | 32 |
experimental model | 31 |
pearson correlation | 31 |
one dog | 31 |
paediatric patients | 31 |
hour period | 31 |
cell recovery | 31 |
weeks post | 31 |
continuous intravenous | 31 |
nasal cannula | 31 |
donor cell | 31 |
common practice | 31 |
mg iv | 31 |
extremely rare | 31 |
confirmed cases | 31 |
volatile oils | 31 |
support scientific | 31 |
patients discharged | 31 |
hepatic vein | 31 |
patients responded | 31 |
cortisol levels | 31 |
eff ective | 31 |
adverse outcomes | 31 |
aneurysmal sah | 31 |
cognitive impairment | 31 |
interval ci | 31 |
virus replication | 31 |
systolic dysfunction | 31 |
four cases | 31 |
patients older | 31 |
study using | 31 |
recurrence rate | 31 |
higher number | 31 |
health problem | 31 |
laparoscopic repair | 31 |
inflammatory bowel | 31 |
recent study | 31 |
stage ii | 31 |
patient experienced | 31 |
readily available | 31 |
negative results | 31 |
large numbers | 31 |
weight heparin | 31 |
mds patients | 31 |
severe gvhd | 31 |
chest ct | 31 |
will allow | 31 |
first step | 31 |
basal ganglia | 31 |
linear mixed | 31 |
intestinal tract | 31 |
scientific studies | 31 |
venous catheters | 31 |
vascular endothelial | 31 |
mit einer | 31 |
diarrhea virus | 31 |
cells transplantation | 31 |
patients including | 31 |
blood banks | 31 |
children aged | 31 |
life care | 31 |
post infection | 31 |
autologous blood | 31 |
good correlation | 31 |
also measured | 31 |
experimental study | 31 |
oil encapsulated | 31 |
peptic ulcer | 31 |
frequently observed | 31 |
adrenal gland | 31 |
monocentric study | 31 |
thromboembolic events | 31 |
glucose control | 31 |
clinical care | 31 |
regression analyses | 31 |
upper limit | 31 |
cellular immune | 31 |
neuromuscular blockade | 31 |
time intervals | 31 |
hospital acquired | 31 |
sigmoid colon | 31 |
poor neurological | 31 |
viral shedding | 31 |
analysis demonstrated | 31 |
first choice | 31 |
filtration rate | 31 |
study performed | 31 |
muscle mass | 31 |
tumor size | 31 |
urinary catheter | 31 |
phase study | 31 |
bl mice | 31 |
medicated lozenges | 31 |
disease caused | 31 |
allogeneic transplant | 31 |
bloodstream infection | 31 |
mortality compared | 31 |
fluid overload | 31 |
achieved complete | 31 |
significant clinical | 31 |
nkg dl | 31 |
also higher | 31 |
acute coronary | 31 |
still remains | 31 |
lower mortality | 31 |
vitro studies | 31 |
lps challenge | 31 |
transfusion reaction | 31 |
respiratory effort | 31 |
additional studies | 31 |
normal subjects | 31 |
chronic myeloid | 31 |
female ratio | 31 |
dose reduction | 31 |
affected dogs | 31 |
study confirms | 31 |
time periods | 31 |